JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Pfizer – ervogastat and two preclinical assets – as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal's brand becoming intrinsically linked to MASH treatment. The commercial performance of Rezdiffra (resmetirom) provides clear validation for Madrigal's goals. Rezdiffra reached $287m in net sales during Q3 2025, with annualised revenue exceeding $1bn in the sixth quarter post-launch. The 10,000+ prescribers and more than 29,500 active patients demonstrate genuine and widespread clinical uptake driven by a differentiated once-daily oral profile. These metrics show that Madrigal has successfully identified and addressed unmet need in a historically challenging therapeutic area. With the current MASH market at only $180m across two approved products,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Jumps on Higher Wegovy Dose [Yahoo! Finance]Yahoo! Finance
- The Fastest Path To Greenland Runs Through Novo Nordisk [Forbes]Forbes
- Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more [CNBC]CNBC
- Fat jabs could lead to cheaper air fares [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website